UNITY Biotechnology will host a virtual event on March 24, 2025, discussing UBX1325's Phase 2b ASPIRE study results.
Quiver AI Summary
UNITY Biotechnology, Inc. has announced a virtual investor event scheduled for March 24, 2025, at 8:00 AM ET, featuring Dr. Robert Bhisitkul from UCSF School of Medicine and company management. The event will discuss the 24- and 36-week results from the Phase 2b ASPIRE study of UBX1325, a potential treatment for diabetic macular edema (DME). UBX1325 is a small molecule BCL-xL inhibitor that selectively targets senescent cells to potentially improve long-term visual outcomes. Previous studies indicated that UBX1325 significantly improved visual acuity in DME patients. UNITY focuses on developing therapies aimed at tackling aging-related diseases by targeting senescent cells.
Potential Positives
- UNITY Biotechnology is hosting a virtual investor event to present significant study results, showcasing transparency and engagement with stakeholders.
- Prominent key opinion leader Robert Bhisitkul, MD, PhD, will be featured, which enhances credibility and interest in the company's research.
- Results from the Phase 2b ASPIRE study on UBX1325 are being shared, indicating ongoing progress in the development of a potentially transformative treatment for retinal diseases.
- UBX1325 has shown statistically significant improvements in clinical trials, suggesting promising efficacy and safety, which could appeal to investors and the medical community.
Potential Negatives
- The press release emphasizes that UBX1325 is still an investigational compound and not approved for any use, highlighting regulatory uncertainties that could hinder the company's progress.
- The release focuses on a specific upcoming investor event, indicating that it may be a response to concerns or the need for more engagement with investors about ongoing projects.
- The language surrounding UBX1325’s potential efficacy is cautious and includes terms like "statistically significant" and "clinically meaningful," which may suggest that the results are not overwhelmingly positive or that further validation is needed.
FAQ
What is the purpose of the virtual investor event?
The event will review results from the Phase 2b ASPIRE study on UBX1325 for DME treatment.
Who will be presenting at the investor event?
Ophthalmology KOL Robert Bhisitkul and UNITY management will present at the event.
What is UBX1325 and its significance?
UBX1325 is an investigational compound aimed at treating retinal diseases like DME using senolytic mechanisms.
When is the virtual investor event scheduled?
The event is scheduled for Monday, March 24, 2025, at 8:00 AM ET.
How can I register for the investor event?
You can register for the event by clicking the registration link provided in the announcement.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$UBX Insider Trading Activity
$UBX insiders have traded $UBX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $UBX stock by insiders over the last 6 months:
- ANIRVAN GHOSH (Chief Executive Officer) has made 0 purchases and 2 sales selling 1,074 shares for an estimated $1,988.
- ALEXANDER HIEU NGUYEN (CLO and Head of Ops) has made 0 purchases and 2 sales selling 313 shares for an estimated $557.
- LYNNE MARIE SULLIVAN (CFO & Head of Corp. Dev.) has made 0 purchases and 2 sales selling 289 shares for an estimated $516.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$UBX Hedge Fund Activity
We have seen 12 institutional investors add shares of $UBX stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OCONNOR, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS (LLC) removed 79,354 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $77,481
- CITADEL ADVISORS LLC removed 69,210 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $67,576
- ALYESKA INVESTMENT GROUP, L.P. removed 60,930 shares (-6.6%) from their portfolio in Q4 2024, for an estimated $59,492
- BALLENTINE PARTNERS, LLC removed 57,046 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $55,699
- MORGAN STANLEY added 35,350 shares (+79.1%) to their portfolio in Q4 2024, for an estimated $34,515
- BRIDGEWAY CAPITAL MANAGEMENT, LLC added 25,000 shares (+100.0%) to their portfolio in Q4 2024, for an estimated $24,410
- JANE STREET GROUP, LLC added 21,179 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,679
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
SOUTH SAN FRANCISCO, Calif., March 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that it will host a virtual investor event on Monday, March 24, 2025, at 8:00 AM ET. To register, click here .
The event will feature prominent ophthalmology key opinion leader (KOL) Robert Bhisitkul, MD, PhD from the UCSF School of Medicine, who will join company management to review 24- and 36-week results from the Phase 2b ASPIRE study evaluating the safety and efficacy of UBX1325 in patients with DME. UBX1325 is a potent BCL-xL inhibitor that acts via a senolytic mechanism of action, with the potential to improve long-term visual outcomes.
A live question and answer session will follow the formal presentations.
About UBX1325
UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting BCL-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease.
About UNITY
UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at
www.unitybiotechnology.com
or follow us on
X
and
LinkedIn
.
Media Contact
Inizio Evoke Comms
Katherine Smith
[email protected]
Investor Contact
LifeSci Advisors, LLC
Joyce Allaire
[email protected]
